Diversity in diabetes: The role of insulin aspart

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 1, 2012, Pages 50-61

  Heller, Simon ^a   McCance, David R ^b   Moghissi, Etie ^c   Nazeri, Avideh ^d   Kordonouri, Olga ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NOVO NORDISK A S   (Denmark)

^e Children's Hospital   (Germany)

Author keywords

Children; Diabetes; Elderly; Insulin aspart; Pregnancy; Rapid acting insulin analogues

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; STEROID; SULFONYLUREA;

CARBOHYDRATE INTAKE; CLINICAL TRIAL (TOPIC); DEMOGRAPHY; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; EMERGENCY WARD; FEEDING BEHAVIOR; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INTENSIVE CARE UNIT; LOW BIRTH WEIGHT; MORBIDITY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PREMATURE LABOR; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SCHOOL HEALTH NURSING; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INPATIENTS; INSULIN ASPART; PREGNANCY; YOUNG ADULT;

EID: 84855369118     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1240     Document Type: Review

References (71)

1. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G; EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373: 2027-2033.
2. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005; 146: 693-700.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
4. Chaturvedi N. Metabolic memory in the autonomic neuropathy of diabetes. Implications for pathogenesis and patient care. Circulation 2009; 119: 2886-2893.
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
6. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
7. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. Br Med J 2010; 340: b5444. doi:10.1136.
8. Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-954.
9. Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med 2008; 121(6 Suppl.): S9-S19.
10. Nosek L, Heinemann L, Kaiser M, et al. No increase in the duration of action with rising doses of insulin aspart. Diabetes 2003; 52(Suppl. 1): A128.
11. Becker RH, Frick AD, Nosek L, Heinemann L, Rave K. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care 2007; 30: 2506-2507.
12. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
13. Kapellen TM, Wolf J, Rosenbauer J, et al. Changes in the use of analogue insulins in 37 206 children and adolescents with type 1 diabetes in 275 German and Austrian centers during the last twelve years. Exp Clin Endocrinol Diabetes 2009; 117: 329-335.
14. Danne T, Aman J, Schober E, et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26: 2359-2364.
15. Danne T, Råstam J, Odendahl R, et al. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes. Pediatr Diabetes 2007; 8: 278-285.
16. Fairchild JM, Ambler GR, Genoud-Lawton CH, et al. Insulin lispro versus regular insulin in children with type 1 diabetes on twice daily insulin. Pediatr Diabetes 2000; 1: 135-141.
17. Alemzadeh R, Palma-Sisto P, Parton E, Totka J, Kirby M. Beneficial effects of flexible insulin therapy in children and adolescents with type 1 diabetes mellitus. Acta Diabetol 2003; 40: 137-142.
18. Martin D, Licha-Müntz G, Grasset E, et al. Efficacy of Humalog injections before an afternoon meal and their acceptance by children and adolescents with type 1 diabetes. Diabet Med 2002; 19: 1026-1031.
19. Holcombe JH, Zalani S, Arora VK, Mast CJ; Lispro in Adolescents Study Group. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002; 24: 629-638.
20. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005; 28: 2100-2105.
21. Danne T. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus. Clin Ther 2007; 29(Suppl. D): S145-S152.
22. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000; 159: 483-488.
23. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21: 1904-1909.
24. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999; 22: 801-805.
25. Weinzimer SA, Ternand C, Howard C, et al. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care 2008; 31: 210-215.
26. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27: 1554-1558.
27. Holl R, Grabert M. Deutscher Gesundheitsbericht Diabetes 2009. Accessed 24 November 2010.
28. Holmberg H, Mersebach H, Kanc K, Ludvigsson J; Insulin Aspart Study Group on Immunogenicity. Antibody response to insulin in children and adolescents with newly diagnosed type 1 diabetes. Diabet Med 2008; 25: 792-797.
29. Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. Br Med J 2004; 328: 915.
30. Confidential Enquiry into Maternal and Child Health. Pregnancy in Women with Type 1 and Type 2 Diabetes in 2002-03, England, Wales and Northern Ireland. CEMACH: London, 2005.
31. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2010; 33(Suppl. 1): S11-S61.
32. NICE Clinical Guideline 63. Diabetes in pregnancy. Accessed 24 November 2010.
33. Temple R, Aldridge V, Greenwood R, Heyburn P, Sampson M, Stanley K. Association between outcome of pregnancy and glycaemic control in early pregnancy in type 1 diabetes: population-based study. Br Med J 2002; 325: 1275-1276.
34. Lepercq J, Coste J, Theau A, Dubois-Laforgue D, Timsit J. Factors associated with preterm delivery in women with type 1 diabetes: a cohort study. Diabetes Care 2004; 27: 2824-2828.
35. DCCT Author Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996; 174: 1343-1353.
36. Ter Braak EW, Evers IM, Willem Erkelens D, Visser GH. Maternal hypoglycaemia during pregnancy in type 1 diabetes: maternal and fetal consequences. Diabetes Metab Res Rev 2002; 18: 96-105.
37. Rosenn BM, Miodovonik M, Holcberg G, Khoury JC, Siddiqi TA. Hypoglycemia: the price of intensive insulin therapy for pregnant women with insulin-dependent diabetes mellitus. Obstet Gynecol 1995; 85: 417-422.
38. Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30: 771-776.
39. Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008; 198: 186.e1-186.e7.
40. McCance DR, Damm P, Mathiesen ER, et al. Evaluation of insulin antibodies and placental transfer of insulin aspart in pregnant women with type 1 diabetes mellitus. Diabetologia 2008; 51: 2141-2143.
41. Heller S, Damm P, Mersebach H, et al. Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized study. Diabetes Care 2010; 33: 473-477.
42. Pettitt DJ, Ospina P, Howard C, Zisser H, Jovanovic L. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med 2007; 24: 1129-1135.
43. DCCT Author Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
44. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
45. Yamagishi S, Matsui T, Ueda S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. Cardiovasc Hematol Agents Med Chem 2007; 5: 236-240.
46. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1 c). Diabetes Care 2003; 26: 881-885.
47. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl. 3): S18-S24.
48. Home PD, Lindholm A, Riis A; European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000; 17: 762-770.
49. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-588.
50. Bretzel RG, Arnolds S, Medding J, Linn T. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004; 27: 1023-1027.
51. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004; 21: 769-775.
52. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.
53. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
54. Garber AJ, Moghissi ES, Bransome ED Jr, et al. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract 2004; 10: 77-82.
55. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27: 553-591.
56. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract 2009; 15: 353-369.
57. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006; 29: 1955-1962.
58. Umpierrez GE, Palacio A, Smiley D. Sliding scale insulin use: myth or insanity? Am J Med 2007; 120: 563-567.
59. Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size. Clin Ther 2004; 26: 1492-1497.
60. Brunner GA, Hirschberger S, Sendlhofer G, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000; 17: 371-375.
61. Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 2004; 27: 1873-1878.
62. Munoz C, Villanueva G, Fogg L, et al. Impact of a Subcutaneous Insulin Protocol in the Emergency Department: Rush Emergency Department Hyperglycemia Intervention (REDHI). J Emerg Med 2011; 40: 493-498.
63. Bernard J, Munoz C, Harper J, Muriello M, Rico E, Baldwin D. An inpatient insulin protocol with subcutaneous (SQ) aspart (A) and detemir (D) for the management of hyperglycemia beginning in the emergency department (ED): a randomized trial in comparison with usual care. Diabetes 2009; 58(Suppl. 1):Abstract 2002-PO.
64. Udwadia F, Bhattachayya A, Seshaiah V, et al. Management of In-Patient Hyperglycemia: Safety of Intensive Intravenous Insulin Aspart. IDF 2009 20th World Congress Abstract Book. Montreal: IDF: 2009; 495 (Poster P-1462).
65. Hornick T, Aron DC. Managing diabetes in the elderly: go easy, individualize. Cleve Clin J Med 2008; 75: 70-78.
66. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997; 46: 701-710.
67. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007; 64: 570-575.
68. Del Prato S, Heine RJ, Keilson L, et al. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care 2003; 26: 2075-2080.
69. Neumiller JJ, Setter SM, Gates BJ, et al. Pharmacological management of glycemic control in the geriatric patient with type 2 diabetes mellitus. Consult Pharm 2009; 24: 45-63.
70. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005; 60: 469-476.
71. Krones R, Schütte C, Heise T. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Diabetes Obes Metab 2009; 11: 41-44.